Influence of hypotensive drugs on lipopolysaccharide (LPS)-induced serum concentrations of tumor necrosis factor alpha (TNF-α), interleukin (IL)-1β, IL-6 in spontaneously hypertensive rats (SHR)

Pharmacological Reports

Volumn 59, Issue SUPPL. 1, 2007, Pages 183-191

  Andrzejczak, Dariusz ^a   Górska, Dorota ^a   Czarnecka, Elzbieta ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Amlodipine; Cytokines; Doxazosin; Indapamide; LPS; Proinflammatory; Propranolol; SHR

Indexed keywords

AMLODIPINE; ANTIHYPERTENSIVE AGENT; CHOLESTEROL; DOXAZOSIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INDAPAMIDE; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; METHYLCELLULOSE; PROPRANOLOL; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; FEEDING; HYPERTENSION; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PROTEIN BLOOD LEVEL; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; STATISTICAL SIGNIFICANCE; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION;

EID: 38049126187     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Andrzejczak D, Górska D, Czarnecka E: Influence of amlodipine and atenolol on lipopolysaccharide (LPS)-induced serum concentrations of TNF-α, IL-1β, IL-6 in spontaneously hypertensive rats (SHR). Pharmacol Rep. 2006, 58, 711-719.
2. Bautista LE, Vera LM, Arenas IA, Gamarra G: Independent association between inflammatory markers (C-reactive protein, interleukin-6, and TNF-α) and essential hypertension. J Hum Hypertens, 2005, 19, 149-154.
3. Bergmann M, Sautner T. Immunomodulatory effects of vasoactive catecholamines. Wien Klin Wochenschr, 2002, 114, 752-761.
4. Chae CU, Lee RT, Rifai N, Ridker PM: Blood pressure and inflammation in apparently healthy men. Hypertension, 2001, 38, 399-403.
5. Chou TC, Yang SP, Pei D: Amlodipine inhibits pro-inflammatory cytokines and free radical production and inducible nitric oxide synthase expression in lipopoly-saccharide/interferon-gamma-stimulated cultured vascular smooth muscle cells. Jpn J Pharmacol, 2002, 89, 157-163.
6. Dalekos GN., Elisaf M., Bairaktari E., Tsolas O., Siamopoulos KC: Increased serum levels of interleukin-1beta in the systemic circulation of patients with essential hypertension: additional risk factor for atherogenesis in hypertensive patients? J Lab Clin Med, 1997, 129, 300-308.
7. Dandona P, Aljada A, Chaudhuri A, Mohant P, Garg R: Metabolic Syndrome: A Comprehensive Perspective Based on Interactions Between Obesity, Diabetes, and Inflammation. Circ Res, 2005, 111, 1448-1454.
8. Dredge K, Connor TJ, Kelly JP, Leonard BE: Differential effect of a single high dose of the tricyclic antidepressant imipramine on interleukin-1β and tumor necrosis factor-α secretion following an in vivo lipopolysaccharide challenge in rats. Int J Immunopharmacol, 1999, 21, 663-673.
9. Eisenhui T, Sinha B, Grotirup-Wolfers E, Semmler J, Siess W, Endres S: Prostacyclin analogs suppress the synthesis of turner necrosis factor-alpha in LPS-stimulated human peripheral blood mononuclear cells. Immunopharmacology, 1993, 26, 259-264.
10. Elenkov IJ, Wilder RL, Chrousos GP, Vizi ES: The sympathetic nerve - an integrative interface between two supersystems: the brain and the immune system. Pharmacol Rev. 2000, 52, 595-638.
11. Ersoy C, Imamodlu S, Budak F, Tuncel, E Ertürk E, Oral B: Effect of amlodipine on insulin resistance and tumor necrosis factor-alpha levels in hypertensive obese type 2 diabetic patients. Indian J Med Res, 2004, 120, 481-488.
12. Fleet JC, Clinton SK, Salomon RN, Loppnow H, Libby P: Atherogenic diets enhance endotoxin-stimulated interleukin-1 and tumor necrosis factor gene expression in rabbit aortae. J Nutr. 1992, 122, 294-305.
13. Fukuzawa M, Satoh J, Ohta S, Takahashi K, Miyagauchi S, Qiang X, Sakata Y et al.: Modulation of tumor necrosis factor-α production with anti-hypertensive drug. Immunopharmacology, 2000, 48, 65-74.
14. Henninger DD, Gerritsen ME, Granger DN: Low-density lipoprotein receptor knockout mice exhibit exaggerated microvascular responses to inflammatory stimuli. Circ Res, 1997, 81, 2714-281.
15. Justrzebski M, Czarnecka D, Rajzer M, Kaweeka-Jaszcz K: Increased levels of inflammatory markers in hypertensives with target organ damage. Kardiol Pol, 2006, 64, 802-809.
16. Kavelaars A: Regulated expression of α-1 adrenergic receptors in the immune system. Brain Behav Immunol, 2002, 16, 799-807.
17. Kaynar K, Ulusoy S, Ovali E, Vartizor B, Dikmen T, Gul S: TGF-β and TNF-α producing effects of losartan and amlodipine on human mononuclear cell culture. Nephrology, 2005, 10, 478-482.
18. Mason RP, Marche P, Hintze TH: Novel vascular biology of third-generation 1-type calcium channel antagonists. Ancillary actions of amlodipine. Arterioscler Thromb Vasc Biol. 2003, 23, 2155-2163.
19. Mastronardi CA, Yu WH, McCann S: Lipopolysaccharide-induced tumor necrosis factor-α release is controlled by the central nervous syqtern. Neuro-immunomodulation, 2001, 9, 148-156.
20. Matsumori A, Ono K, Nishio R, Nose Y, Sasayama S: Amlodipine inhibits the production of cytokines induced by ouabain. Cytokine, 2000, 12, 294-297.
21. Monastra, G, Secchi EF: Beta-adrenergic receptors mediate in vivo the adrenaline inhibition of lipopolysaccharide-induced necrosis factor release. Immunol Lett, 1993, 38, 127-130.
22. Pirich C. Schmid P, Fitscha P, Wytek R. O'Grady J, Sinzinger H: Influence of calcium antagonists on platelet function and vascular prostacyclin production. Blood Press Suppl, 1994, 1, 75-80.
23. Rödler S, Roth M, Nauck M, Tamm M, Block LH: Ca 2)-channel blockers modulate the expression of interleukin-6 and interleukin-8 genes in human vascular smooth muscle, cells. J Moll Cell Cardiol, 1995, 27, 2295-2302.
24. Ross R: Atherosclerosis an inflammatory disease. N Engl J Med, 1999, 340, 115-126.
25. Roth M, Keul R, Emmons LR, Hörl WH, Block LH: Manidipine regulates the transcription of cytokine genes. Proc Natl Acad Sci USA, 1992, 89, 4071-4075.
26. Salomon P, Halawa B, Karolko B: Influence of amlodipine on serum level of some cytokines in patients with congestive heart failure (Polish). Pol Arch Med Wewn, 2003, 109, 149-155.
27. Sanz-Rosa D, Oubina MP, Cediel E, de Las Heras N, Vegazo O, Jimenez J, Lahera V, Cachofeiro V: Effect of AT1 receptor antagonism on vascular and circulating inflammatory mediators in SHR: role of NF-kappaB/IkappaB system. Am J Physiol Heart Circ Physiol, 2005, 288, H111-H115.
28. Savoia C, Schiffrin EL: Inflammation in hypertension. Curr Opin Nephrol Hypertens, 2006, 15, 152-158.
29. Siragy HM, Xue C, Webb RL: Beneficial effects of combined benazepril-amlodipilie on cardiac nitric oxide, cGMP, and TNF-alpha production after cardiac ischemia. J Cardiovase Pharmacol, 2006, 47, 636-642.
30. Sun L, Gao YH, Tian DK, Zheng JP, Zhu CY, Ke Y, Bian K: Inflammation of different tissues in spontaneously hypertensive rats. Acta Physiol Sin (Sheng Li Xue Bao), 2006, 58, 318-323.
31. Tamura A, Sato T, Fujii T: Antioxidant activity of indapamide and its metabolite. Chem Pharm Bull (Tokyo), 1990, 38, 255-257.
32. Uehara Y, Shirahase H, Nagata T, Ishimitsu T, Morishita S, Osumi S, Matsuoka, H, Sugimoto T: Radical scavengers of indapamide in prostacyclin synthesis in rat smooth muscle cell. Hyperlension, 1990, 15, 216-224.
33. Ueshiba H, Miyachi Y: Eflect of doxazosin on insulin resistance in hypertensive patients with obesity. Horm Metab Res, 2003, 35, 532-536.
34. Vergely C, Walker MK, Zeller M, Rademakers JR, Maupoil V, Schiavi P, Guez D, Rochette L: Antioxidant properties of indapamide, 5-OH indapamide and hydrochlorothiazide evaluated by oxygen-radical absorbing capacity and electron paramagnetic resonance. Mol Cell Biochem. 1998, 178, 151-155.
35. Walz G, Zanker B, Barth C, Wieder KJ, Clark SC, Strom TB: Transcriptional modulation of human IL-6 gene expression by verapamil. J Immunol, 1990, 144, 4242-42248.
36. Wang JF, Meissner A, Malek S, Chen Y, Ke Q, Zharig J, Chu V et al.: Propranolol ameliorates and epinephrine exacerbates progression of acute and chronic viral myocarditis. Am J Physiol Heart Circ Physiol, 2005, 289, H1577-H1583.
37. Wisse BE: The Inflammatory Syndrome: The Role of Adipose Tissue Cytokines in Metabolic Disorders Linked to Obesity. J Am Soc Nephrol, 2004, 15, 2792-2800.
38. Xie QY, Wang YJ, Sun ZL, Yang TL: Effecrs of valsartan and indapamide on plasma cytokines in essential hypertension. Zhong Nan Da Xue Xue Bao Yi Xue Ban, 2006, 31, 629-634. (abstract)
39. Yoshimura T, Kurita C, Nagao T, Usami E, Nakao T, Watanabe S, Kobayashi J et al.: Inhibition of tumor necrosis factor-alpha and interleukin-1-beta production by beta-adrenoceptor agonists from lipopolysaccharide-stimulated human peripheral blood mononuclear cells. Pharmacology, 1997, 54, 144-152.
40. Zidek Z: Adenosine-cyclic AMP pathways and cytokine expression. Eur Cytokine Netw, 1999, 10, 319-328.